» Articles » PMID: 33424833

Vi-Vaccinations Induce Heterogeneous Plasma Cell Responses That Associate With Protection From Typhoid Fever

Abstract

Vi-polysaccharide conjugate vaccines are efficacious against cases of typhoid fever; however, an absolute correlate of protection is not established. In this study, we investigated the leukocyte response to a Vi-tetanus toxoid conjugate vaccine (Vi-TT) in comparison with a plain polysaccharide vaccine (Vi-PS) in healthy adults subsequently challenged with Typhi. Immunological responses and their association with challenge outcome was assessed by mass cytometry and Vi-ELISpot assay. Immunization induced significant expansion of plasma cells in both vaccines with modest T follicular helper cell responses detectable after Vi-TT only. The Vi-specific IgG and IgM B cell response was considerably greater in magnitude in Vi-TT recipients. Intriguingly, a significant increase in a subset of IgA plasma cells expressing mucosal migratory markers α4β7 and CCR10 was observed in both vaccine groups, suggesting a gut-tropic, mucosal response is induced by Vi-vaccination. The total plasma cell response was significantly associated with protection against typhoid fever in Vi-TT vaccinees but not Vi-PS. IgA plasma cells were not significantly associated with protection for either vaccine, although a trend is seen for Vi-PS. Conversely, the IgA fraction of the plasma cell response was only associated with protection in Vi-TT. In summary, these data indicate that a phenotypically heterogeneous response including both gut-homing and systemic antibody secreting cells may be critical for protection induced by Vi-TT vaccination.

Citing Articles

The use of controlled human infection models to identify correlates of protection for invasive vaccines.

McCann N, Vicentine M, Kim Y, Pollard A Front Immunol. 2024; 15:1457785.

PMID: 39257585 PMC: 11385307. DOI: 10.3389/fimmu.2024.1457785.


Intranasal immunization of mice with chimera of Salmonella Typhi protein elicits protective intestinal immunity.

Chakraborty S, Dutta P, Pal A, Chakraborty S, Banik G, Halder P NPJ Vaccines. 2024; 9(1):24.

PMID: 38321067 PMC: 10847434. DOI: 10.1038/s41541-024-00812-4.


Typhoid fever.

Meiring J, Khanam F, Basnyat B, Charles R, Crump J, Debellut F Nat Rev Dis Primers. 2023; 9(1):71.

PMID: 38097589 DOI: 10.1038/s41572-023-00480-z.


Molecular correlates of vaccine-induced protection against typhoid fever.

Zhu H, Chelysheva I, Cross D, Blackwell L, Jin C, Gibani M J Clin Invest. 2023; 133(16).

PMID: 37402153 PMC: 10425215. DOI: 10.1172/JCI169676.


Controlled human infectious models, a path forward in uncovering immunological correlates of protection: Lessons from enteric fevers studies.

Sztein M, Booth J Front Microbiol. 2022; 13:983403.

PMID: 36204615 PMC: 9530043. DOI: 10.3389/fmicb.2022.983403.


References
1.
Tobar J, Gonzalez P, Kalergis A . Salmonella escape from antigen presentation can be overcome by targeting bacteria to Fc gamma receptors on dendritic cells. J Immunol. 2004; 173(6):4058-65. DOI: 10.4049/jimmunol.173.6.4058. View

2.
Wang W, Soto H, Oldham E, Buchanan M, Homey B, CATRON D . Identification of a novel chemokine (CCL28), which binds CCR10 (GPR2). J Biol Chem. 2000; 275(29):22313-23. DOI: 10.1074/jbc.M001461200. View

3.
Kantele A, Pakkanen S, Karttunen R, Kantele J . Head-to-head comparison of humoral immune responses to Vi capsular polysaccharide and Salmonella Typhi Ty21a typhoid vaccines--a randomized trial. PLoS One. 2013; 8(4):e60583. PMC: 3620468. DOI: 10.1371/journal.pone.0060583. View

4.
Nieminen T, Eskola J, Kayhty H . Pneumococcal conjugate vaccination in adults: circulating antibody secreting cell response and humoral antibody responses in saliva and in serum. Vaccine. 1998; 16(6):630-6. DOI: 10.1016/s0264-410x(97)00235-1. View

5.
Gorfu G, Rivera-Nieves J, Ley K . Role of beta7 integrins in intestinal lymphocyte homing and retention. Curr Mol Med. 2009; 9(7):836-50. PMC: 2770881. DOI: 10.2174/156652409789105525. View